News | May 14, 2024
Lonza reports softer performance in Q1 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
The company is committed to address this observation comprehensively within stipulated time
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
